

WEST

Help

Logout

Interrupt

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Preferences

Cases

Search Results -

Term	Documents
LAZARUS-ANDREWS	0
LAZARUS-ANDREWS	0
LAZARUS-ANDREWS.USPT,PGPB,JPAB,EPAB,DWPI.	0
(LAZARUS-ANDREWS).USPT,PGPB,JPAB,EPAB,DWPI.	0

Database:

US Patents Full-Text Database

US Pre-Grant Publication Full-Text Database

JPO Abstracts Database

EPO Abstracts Database

Derwent World Patents Index

IBM Technical Disclosure Bulletins

Search:

L7

Refine Search

	PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/>	<u>5247069</u>	September 1993	Ledbetter et al.	530/350
<input type="checkbox"/>	<u>5434131</u>	July 1995	Linsley	514/2
<input type="checkbox"/>	<u>5677165</u>	October 1997	DeBoer et al.	
<input type="checkbox"/>	<u>5747037</u>	May 1998	Noelle et al.	
<input type="checkbox"/>	<u>5869049</u>	February 1999	Noelle et al.	

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
9308207	April 1993	WO	

OTHER PUBLICATIONS

Datta et al. Arthritis and Rheumatism 40: 1735-1745 (1997).*

Tang et al. Eur. J. Immunol. 27: 3143-3150 (1997).*

Foy et al. J Exp Med. 178: 1567-1575 (1993).*

Buhlman et al. J. Clin. Immunol. 16: 83-89 (1996).*

Koshy et al. J. Clin. Invest. 97: 826-837 (1996)*

Desai-Mehta et al. J Immunol. 154: 2063-2073 (1995).*

Early et al. J. Immunol. 157: 3159-3164 (1996).*

Durie et al. Science 261: 1328-1330 (1993).*

Carayanniotis et al. Immunology 90: 421-426 (1997).*

Griggs et al. J Exp Med. 183: 801-810 (1996).*

Balasa et al. J Immunol. 159: 4620-4627 (1997).*

Biacone J Exp Med. 183: 1473-1481 (1996).*

Kunzendorfer et al. Kidney and Blood Press. Res 19: 201-204 (1996).*

Mohan et al. J. Immunol. 154: 1470-1480 (1995).*

Aruffo et al. Cell 61: 1303-1313 (1990).*

Stamenkovic Embo J. 8: 1403-1410 (1989).*

Biacone et al. Kidney International 48: 458-468 (1995).*

Stuber et al. J Exp Med. 183: 693-698 (1996).*

Gray et al. J Exp Med. 180: 141-155 (1994).

ART-UNIT: 164

PRIMARY-EXAMINER: Gambel; Phillip

ATTY-AGENT-FIRM: Henry; Janis C.

ABSTRACT:

There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor. Also disclosed are methods of inhibiting undesirable immune responses, preventing T cell interaction with B cells by blocking CD40L binding to CD40 sites on B cells and other target cells.

2 Claims, 31 Drawing figures



Generate Collection

L6: Entry 16 of 19

File: USPT

Jul 24, 2001

US-PAT-NO: 6264951

DOCUMENT-IDENTIFIER: US 6264951 B1

TITLE: Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L

DATE-ISSUED: July 24, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armitage; Richard J.	Bainbridge Island	WA		
Fanslow; William C.	Federal Way	WA		
Spriggs; Melanie K.	Seattle	WA		
Srinivasan; Subhashini	Kirkland	WA		
Gibson; Marylou G.	Carlsbad	CA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Immunex Corporation	Seattle	WA			02

APPL-NO: 08/ 769819 [PALM]

DATE FILED: December 19, 1996

PARENT-CASE:

CROSS REFERENCE TO RELATED APPLICATION This application is a divisional of U.S. patent application Ser. No. 08/484,624, filed Jun. 7, 1995, now U.S. Pat. No. 5,962,406 which is a continuation-in-part application of U.S. patent application Ser. No. 08/249,189, filed May 24, 1994, now U.S. Pat. No. 5,961,974, which is a continuation-in-part of U.S. patent application Ser. No. 07/969,703, filed Oct. 23, 1992, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 07/805,723, filed on Dec. 5, 1991, now abandoned, which is a continuation-in-part of U.S. patent application Ser. No. 07,783,707, filed on Oct. 25, 1991, now abandoned.

INT-CL: [07] A61 K 38/17, A61 K 38/19, C07 K 14/47, C07 K 14/52

US-CL-ISSUED: 424/184.1; 424/185.1, 424/85.1, 514/2, 514/8, 514/12, 514/885, 530/350, 530/351

US-CL-CURRENT: 424/184.1; 424/185.1, 424/85.1, 514/12, 514/2, 514/8, 514/885, 530/350, 530/351

FIELD-OF-SEARCH: 514/2, 514/8, 514/12, 514/885, 424/130.1, 424/133.1, 424/141.1, 424/144.1, 424/153.1, 424/154.1, 424/173.1, 424/134.1, 424/184.1, 424/185.1, 424/85.1, 530/350, 530/351

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected

Search ALL



Generate Collection

L6: Entry 16 of 19

File: USPT

Jul 24, 2001

DOCUMENT-IDENTIFIER: US 6264951 B1

TITLE: Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L

Abstract Text (1):

There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor. Also disclosed are methods of inhibiting undesirable immune responses, preventing T cell interaction with B cells by blocking CD40L binding to CD40 sites on B cells and other target cells.

Detailed Description Text (161):

A similar CD40-L construct was made without an amino terminal FLAG.TM. sequence. This construct utilized an existing Bam HI site at nucleotide 351 in the CD40-L sequence and the downstream PCR oligonucleotide primer described above (SEQ ID NO:19). After amplification of the CD40 sequence with a 5' upstream oligonucleotide homologous to CD40-L nucleotides 324-346, and the downstream primer which introduced a Not I site, the PCR product was cut with Bam HI and Not I and ligated into pAcGP67A cut with Bam HI and NotI. This construct was cotransfected into SF21 cells along with viral DNA as previously described, and recombinant virus was plaque purified, expanded and used to infect insect cells to produce serum free conditioned supernatants. CD40-L was detectable in these crude supernatants by both CD40Fc receptor binding assay and by detection of an 18 Kd band on a Coomassie Blue-stained PAGE. Similar constructs were also prepared for human CD40-L.

C07K016/40 A61K038/17.

[Generate Collection](#)[Print](#)

Term	Documents
"18"	4602590
18S	2822
KDA	22034
KDAS	13
KD	27918
KDS	367
(5 AND ((KDA OR KD) SAME "18")).USPT,PGPB,JPAB,EPAB,DWPI.	19
(L5 AND (18)SAME(KDA OR KD)).USPT,PGPB,JPAB,EPAB,DWPI.	19

[Previous Page](#)[Next Page](#)

Term	Documents
"18"	4602590
18S	2822
KDA	22034
KDAS	13
KD	27918
KDS	367
(5 AND ((KDA OR KD) SAME "18")).USPT,PGPB,JPAB,EPAB,DWPI.	19
(L5 AND (18)SAME(KDA OR KD)).USPT,PGPB,JPAB,EPAB,DWPI.	19

[Previous Page](#)

[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 19 returned.**

-
- ☐ 1. [20030104558](#). 23 Aug 02. 05 Jun 03. Secreted and transmembrane polypeptides and nucleic acids encoding the same. Ashkenazi, Avi J., et al. 435/69.1; 435/183 435/320.1 435/325 530/350 536/23.2 C12P021/02 C12N005/06 C07K014/435 C07H021/04 C12N009/00.
-
- ☐ 2. [20030099642](#). 29 Jun 99. 29 May 03. THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40L) MONOCLONAL ANTIBODY 5C8 IN THE TREATMENT OF VASCULITIS. YELLIN, MICHAEL J., et al. 424/144.1; A61K039/395.
-
- ☐ 3. [20030044902](#). 01 Feb 02. 06 Mar 03. Secreted and transmembrane polypeptides and nucleic acids encoding the same. Ashkenazi, Avi J., et al. 435/69.1; 435/183 435/320.1 435/325 530/350 536/23.2 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/435.
-
- ☐ 4. [20030044844](#). 01 Feb 02. 06 Mar 03. Secreted and transmembrane polypeptides and nucleic acids encoding the same. Ashkenazi, Avi J., et al. 435/7.1; 435/183 435/320.1 435/325 435/69.1 530/350 530/388.1 536/23.2 G01N033/53 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/435 C07K016/40.
-
- ☐ 5. [20030040014](#). 01 Feb 02. 27 Feb 03. Secreted and transmembrane polypeptides and nucleic acids encoding the same. Ashkenazi, Avi J., et al. 435/7.1; 435/183 435/320.1 435/325 435/69.1 530/350 530/388.1 536/23.2 G01N033/53 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/435 C07K016/40.
-
- ☐ 6. [20030032063](#). 01 Feb 02. 13 Feb 03. Secreted and transmembrane polypeptides and nucleic acids encoding the same. Ashkenazi, Avi J., et al. 435/7.1; 435/183 435/320.1 435/325 435/69.1 530/350 530/388.1 536/23.2 G01N033/53 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/435 C07K016/40.
-
- ☐ 7. [20030032062](#). 01 Feb 02. 13 Feb 03. Secreted and transmembrane polypeptides and nucleic acids encoding the same. Ashkenazi, Avi J., et al. 435/7.1; 435/183 435/320.1 435/325 435/69.1 530/350 530/388.1 536/23.2 G01N033/53 C12P021/06 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/435 C07K016/40.
-
- ☐ 8. [20030032057](#). 15 Nov 01. 13 Feb 03. Secreted and transmembrane polypeptides and nucleic acids encoding the same. Ashkenazi, Avi J., et al. 435/7.1; 435/183 435/320.1 435/325 435/69.1 530/350 530/388.1 536/23.2 G01N033/53 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K016/40 C07K014/435.
-
- ☐ 9. [20020197702](#). 26 Mar 02. 26 Dec 02. Membrane derived caspase-3, compositions comprising the same and methods of use therefor. Krebs, Joseph F., et al. 435/226; 435/252.3 435/254.2 435/320.1 435/325 435/348 435/69.1 536/23.2 C12N009/64 C07H021/04 C12N001/18 C12N005/06 C12P021/02 C12N001/21.
-
- ☐ 10. [20020177165](#). 01 Feb 02. 28 Nov 02. Secreted and transmembrane polypeptides and nucleic acids encoding. Ashkenazi, Avi J., et al. 435/7.1; 435/183 435/320.1 435/325 435/69.1 514/12 530/350 530/388.1 536/23.2 G01N033/53 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/435

[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 19 of 19 returned.**

☐ 11. [20020165166](#). 30 Nov 01. 07 Nov 02. Compounds and methods for the modulation of CD154. Yan, Yibing, et al. 514/19; 206/528 562/623 A61K038/05 C07C259/04 B65D083/04.

☐ 12. [20020155579](#). 20 Mar 02. 24 Oct 02. Membrane derived caspase-3, compositions comprising the same and methods of use therefor. Krebs, Joseph F., et al. 435/226; 435/252.3 435/254.2 435/320.1 435/325 435/348 435/69.1 536/23.2 C12N009/64 C07H021/04 C12P021/02 C12N001/21 C12N001/18 C12N005/06 C12N015/74.

☐ 13. [6479258](#). 31 Jan 00; 12 Nov 02. Non-stochastic generation of genetic vaccines. Short, Jay M. 435/69.1; 530/350 536/23.2. C12P021/06 C07K001/00 C07H021/04.

☐ 14. [6399571](#). 12 Mar 99; 04 Jun 02. Chitinase chitin-binding fragments. Gray, Patrick W., et al. 514/12; 424/94.61 435/209 530/350. A61K038/47 A61K038/16 C07K019/00 C12N009/42.

☐ 15. [6340459](#). 22 Apr 96; 22 Jan 02. Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients. Yellin; Michael J., et al. 424/154.1; 424/130.1 424/133.1 424/135.1 424/141.1 424/143.1 424/144.1 424/153.1 424/173.1 435/7.1 435/7.2 435/7.21 435/7.24 530/387.1 530/387.3 530/388.1 530/388.2 530/388.22 530/388.7 530/388.73 530/388.75. A61K039/395 C07K016/28 G01N033/53.

☐ 16. [6264951](#). 19 Dec 96; 24 Jul 01. Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L. Armitage; Richard J., et al. 424/184.1; 424/185.1 424/85.1 514/12 514/2 514/8 514/885 530/350 530/351. A61K038/17 A61K038/19 C07K014/47 C07K014/52.

☐ 17. [6200951](#). 12 Mar 98; 13 Mar 01. Chitinase chitin-binding fragments. Gray, Patrick W., et al. 514/2; 435/183 435/196 435/209 435/7.8 530/324 530/350. A61K038/04 C12N009/42 C12N009/16 C07K019/00.

☐ 18. [6077673](#). 28 Dec 98; 20 Jun 00. Mouse arrays and kits comprising the same. Chenchik; Alex, et al. 435/6; 422/68.1 435/283.1 435/285.1 435/286.1 435/286.2 435/287.1 435/287.2 435/287.7 435/287.9 435/289.1 435/299.1. C12Q001/68.

☐ 19. [5359039](#). 09 Jul 93; 25 Oct 94. Isolated poxvirus A53R-equivalent tumor necrosis factor antagonists. Smith; Craig A., et al. 530/350; 424/186.1 424/232.1 530/826 536/23.72 930/220. C07K013/00 C07K015/04.

[Generate Collection](#)[Print](#)

ds

Set	Items	Description
S1	1357	E1-E47
S2	19	S1 AND CD40L
S3	8	RD S2 (unique items)
S4	5	(CD40L OR CD40(W)LIGAND) (10N) (18(W)KD OR 18(W)KDA)
S5	2	RD S4 (unique items)
S6	23	(CD40L OR CD40(W)LIGAND) AND (18(W)KD OR 18(W)KDA)
S7	9	RD S6 (unique items)
S8	467	(SOLUBLE(W)CD40L OR SOLUBLE(W)CD40(W)LIGAND)
S9	59	(SOLUBLE(W)CD40L OR SOLUBLE(W)CD40(W)LIGAND) (20N) (INHIBIT? OR SUPPRESS? OR BLOCK?)
S10	28	RD S9 (unique items)
S11	3	(CD40L OR CD40(W)LIGAND) AND (18(W)KD OR 18(W)KDA) (10N) (BL- OCK? OR INHIBIT? OR SUPPRESS? OR PREVENT?)
S12	1	RD S11 (unique items)
?		